Dmytruk Mark E.'s Form 4 filing
Ginkgo Bioworks Holdings, Inc. (DNA) · filed Oct 4, 2022
- Accession no.
- 0000899243-22-032862
- Filed
- Oct 4, 2022
- Trade date
- Sep 30-Oct 3, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $22.6K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Dmytruk Mark E.CIK 0001873507 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 30, 2022 | Class A Common Stock | MOption exerciseAcquired | +16,361 | –F2 | – | 16,361 | Direct | |
| Oct 3, 2022 | Class A Common Stock | SSaleDisposed | −7,259 | $3.12 | −$22,648.08 | 9,102 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 30, 2022 | Class B Common Stock | MOption exerciseDisposed | −16,361 | –F2 | – | 658,133 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.
Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.
Remarks
Chief Financial Officer